文献速递内脏/肾动脉与血管畸形

中期结果改善支持慢性肠系膜缺血继续使用裸金属支架

Improving midterm results justify the continued use of bare-metal stents for endovascular therapy for chronic mesenteric ischemia.
PubMed 文献 · J Vasc Surg · 2019-07-18

该回顾性研究纳入2003至2014年150例慢性肠系膜缺血患者,对腹腔干和肠系膜上动脉行裸金属支架置入。肠系膜上动脉3年一期通畅率早期组59%、晚期组77%(P=.016),开口喇叭口成形与通畅改善独立相关(HR 0.29),支持继续使用裸金属支架。

要点

  • 慢性肠系膜缺血裸金属支架中期结果可接受,经验积累后结果改善。
  • 肠系膜上动脉开口喇叭口成形与通畅改善独立相关(HR 0.29)。
  • 年龄>70岁患者肠系膜上动脉通畅结果优于年轻患者。

核心结论

  • 慢性肠系膜缺血介入治疗中期结果可接受,随着经验和新技术应用结果似有改善。
  • 年龄>70岁患者结果优于年轻患者,可能反映年轻患者病变更具侵袭性。
  • 开口喇叭口成形是多变量分析中唯一与肠系膜上动脉通畅改善相关的因素。
  • 数据支持慢性肠系膜缺血治疗中继续使用裸金属支架。

研究设计与样本

  • 回顾性研究,纳入2003至2014年接受裸金属支架置入的慢性肠系膜缺血患者150例(男39例,女111例;年龄70.7±11.1岁)。
  • 干预腹腔干56支、肠系膜上动脉133支,38例同时干预腹腔干和肠系膜上动脉。
  • 患者分为早期组(2003-2008年)和晚期组(2009-2014年)比较早期与当代结果。
  • 对通畅丢失终点行单变量分析,通畅相关因素进一步行单变量和多变量分析。

主要发现

  • 腹腔干一期通畅率1年86%(95%CI 73-99)、3年66%(95%CI 46-87)。
  • 肠系膜上动脉一期通畅率1年81%(95%CI 72-89)、3年69.0%(95%CI 58-81)。
  • 年龄增加与肠系膜上动脉结果改善相关(HR 0.96;95%CI 0.92-1.00;P=.028)。
  • 肠系膜上动脉慢性完全闭塞通畅结果差于狭窄(HR 2.38;95%CI 1.03-5.47;P=.042)。
  • 年轻患者(<70岁)肠系膜上动脉闭塞比例更高(38.9% vs 22.8;P=.045)。

关键数值与推荐

  • 腹腔干一期通畅率:1年86%(95%CI 73-99),3年66%(95%CI 46-87)。
  • 肠系膜上动脉一期通畅率:1年81%(95%CI 72-89),3年69.0%(95%CI 58-81)。
  • 肠系膜上动脉3年一期通畅率:早期组59% vs 晚期组77%(P=.016)。
  • 开口喇叭口成形与肠系膜上动脉通畅改善独立相关(HR 0.29;95%CI 0.12-0.69;P=.006)。

临床怎么用

  • 慢性肠系膜缺血介入治疗可继续选用裸金属支架。
  • 肠系膜上动脉开口病变可采用开口喇叭口成形技术以改善通畅。
  • 肠系膜上动脉慢性完全闭塞患者需警惕通畅结果较差。
  • 年轻患者(<70岁)病变更具侵袭性,应加强术后监测。

局限性

  • 回顾性研究设计。
  • 单中心经验。
  • 样本量有限(150例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate the contemporary results of interventions in the celiac axis (CA) and superior mesenteric artery (SMA) for chronic mesenteric ischemia (CMI) and factors associated with patency and symptom-free survival. METHODS: A retrospective review of patients with CMI treated with angioplasty and stenting with bare-metal stents from 2003 to 2014 was conducted. Demographic, history, risk factor, preoperative testing, and technical variables were collected and subject to univariate analysis, with end points of patency loss. The patients were divided into early (2003-2008) and late (2009-2014) groups to compare early and contemporary results. Correlates of patency were then subject to further univariate and multivariable analysis. RESULTS: From 2003 to 2014, there were 150 patients (39 men, 111 women; age, 70.7 ± 11.1 years) with CMI who underwent interventions on the CA (56 vessels) and the SMA (133 vessels); 38 patients had both CA and SMA intervention. Primary patency for the CA was 86% (95% confidence interval [CI], 73-99) at 1 year and 66% (95% CI, 46-87) 3 years; for the SMA, primary patency was 81% (95% CI, 72-89) at 1 year and 69.0% (95% CI, 58-81) at 3 years. Increased age was associated with improved results in the SMA (hazard ratio [HR], 0.96; 95% CI, 0.92-1.00; P = .028). Chronic total occlusion in the SMA conferred worse patency compared with stenosis (HR, 2.38; 95% CI, 1.03-5.47; P = .042), and younger patients (<70 years) had a higher proportion of SMA occlusion (38.9% vs 22.8; P = .045). In the SMA, comparing early (2003-2008; 68 patients) vs late (2009-2014; 65 patients), primary patency was better in the late experience (3 years, 59% vs 77%; P = .016). The late cohort was older (early, 68.1 ± 12.5 years vs 72.5 ± 9.7 years; P = .024). The late cohort had a higher incidence of ostial flaring of the stent (early, 44.1%; late, 72.3%; P < .001). Multivariable analysis revealed only ostial flaring to be associated with improved patency in the SMA (HR, 0.29; 95% CI, 0.12-0.69; P = .006). CONCLUSIONS: Intervention for CMI has acceptable midterm results, and with experience and adoption of newer techniques, the results appear to be improving. Patients older than 70 years have better results than younger patients, and this may reflect a more malignant presentation in the younger patients. Ostial flaring proved to be the single factor on multivariate analysis associated with improved patency and was adopted in the late group. These data support the continued use of bare-metal stents in the treatment of CMI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Haben C, Park WM, Bena JF, et al. Improving midterm results justify the continued use of bare-metal stents for endovascular therapy for chronic mesenteric ischemia. J Vasc Surg. 2019. PMID: 31327617. doi:10.1016/j.jvs.2019.01.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。